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Summary
Background Robust evidence of the eﬀ ectiveness of task shifting of antiretroviral therapy (ART) from doctors to other 
health workers is scarce. We aimed to assess the eﬀ ects on mortality, viral suppression, and other health outcomes 
and quality indicators of the Streamlining Tasks and Roles to Expand Treatment and Care for HIV (STRETCH) 
programme, which provides educational outreach training of nurses to initiate and represcribe ART, and to 
decentralise care. 
Methods We undertook a pragmatic, parallel, cluster-randomised trial in South Africa between Jan 28, 2008, and 
June 30, 2010. We randomly assigned 31 primary-care ART clinics to implement the STRETCH programme 
(intervention group) or to continue with standard care (control group). The ratio of randomisation depended on how 
many clinics were in each of nine strata. Two cohorts were enrolled: eligible patients in cohort 1 were adults (aged 
≥16 years) with CD4 counts of 350 cells per μL or less who were not receiving ART; those in cohort 2 were adults who 
had already received ART for at least 6 months and were being treated at enrolment. The primary outcome in cohort 
1 was time to death (superiority analysis). The primary outcome in cohort 2 was the proportion with undetectable viral 
loads (<400 copies per mL) 12 months after enrolment (equivalence analysis, prespeciﬁ ed diﬀ erence <6%). Patients 
and clinicians could not be masked to group assignment. The interim analysis was blind, but data analysts were not 
masked after the database was locked for ﬁ nal analysis. Analyses were done by intention to treat. This trial is 
registered, number ISRCTN46836853.
Findings 5390 patients in cohort 1 and 3029 in cohort 2 were in the intervention group, and 3862 in cohort 1 and 
3202 in cohort 2 were in the control group. Median follow-up was 16·3 months (IQR 12·2–18·0) in cohort 1 and 
18·0 months (18·0–18·0) in cohort 2. In cohort 1, 997 (20%) of 4943 patients analysed in the intervention group and 
747 (19%) of 3862 in the control group with known vital status at the end of the trial had died. Time to death did not 
diﬀ er (hazard ratio [HR] 0·94, 95% CI 0·76–1·15). In a preplanned subgroup analysis of patients with baseline CD4 
counts of 201–350 cells per μL, mortality was slightly lower in the intervention group than in the control group (0·73, 
0·54–1.00; p=0·052), but it did not diﬀ er between groups in patients with baseline CD4 of 200 cells per μL or less 
(0·94, 0·76–1·15; p=0·577). In cohort 2, viral load suppression 12 months after enrolment was equivalent in 
intervention (2156 [71%] of 3029 patients) and control groups (2230 [70%] of 3202; risk diﬀ erence 1·1%, 95% CI 
–2·4 to 4·6).
Interpretation Expansion of primary-care nurses’ roles to include ART initiation and represcription can be done 
safely, and improve health outcomes and quality of care, but might not reduce time to ART or mortality. 
Funding UK Medical Research Council, Development Cooperation Ireland, and Canadian International Develop-
ment Agency.
Introduction
Since 2006, eﬀ orts to increase access to antiretroviral 
therapy (ART) in Africa have emphasised task shifting—
ie, delegation of clinical tasks from doctors to other 
health-care workers.1 However, robust evidence of its 
eﬀ ectiveness is scarce. A 2010 systematic review of task 
shifting in care of patients with HIV infection2 showed 
that it is eﬀ ective and can provide high-quality care, but 
of 25 original studies reviewed, only 11 made com-
parisons with alternatives, and only two of those were 
randomised trials. Neither trial assessed the eﬀ ect of task 
shifting on mortality in people awaiting ART, which in 
both was initiated by doctors.3,4
In South Africa, a major obstacle to ART expansion 
has been the shortage of doctors available to initiate 
treat ment, because of an absolute shortfall and also 
because doctors spend much of their time represcribing 
ART. Delayed ART initiation has resulted in high 
mortality rates in patients who are eligible for ART but 
waiting for treatment .5,6 Thus, evidence from randomised 
trials is needed on whether other health workers can 
eﬀ ectively and safely identify patients eligible for ART, 
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start treatment, and then follow up and represcribe. In 
South Africa, nurses provide most primary care for the 
general population.
Streamlining Tasks and Roles to Expand Treatment 
and Care for HIV (STRETCH) is a complex health 
systems intervention with educational and organ-
isational components. It trains nurses to assume 
responsibility for ART initiation and represcribing. It 
combines an educational outreach training model 
(Practical Approach to Lung Health in South Africa; 
PALSA and PALSA PLUS)7–9—previously shown to 
eﬀ ectively improve care for respiratory disorders, 
tuberculosis, and HIV before ART is used—with 
additional organisational compo nents. STRETCH is 
intended to rationalise ART and other services for 
people with HIV infection, to treat patients already 
stabilised on ART at clinics close to their homes, to 
increase the number of clinics in which ART can be 
initiated, and to raise the number of clinics and nurses 
providing high-quality pretreatment care. The purpose 
of our study was to assess the eﬀ ects of STRETCH on 
mortality, viral suppression, and other health outcomes 
and quality indicators, compared with the present 
system in which only doctors can prescribe ART.
Methods
Study design and participants
We undertook a pragmatic, parallel, cluster-randomised 
trial in the Free State province of South Africa.10 The 
province’s public-sector ART programme started in 2004, 
in designated nurse-led primary-care clinics and doctor-
led hospital outpatient departments. Patients are 
assessed and prepared for ART by nurses and referred to 
doctors for initiation and represcriptions. High mortality 
of patients awaiting treatment initiation by doctors5 
caused the provincial health department to introduce 
STRETCH and to commission us to assess its eﬀ ect on 
outcomes for patients.
We enrolled patients from all 31 clinics participating in 
the ART programme between Jan 28, 2008, and June 30, 
2009, and completed follow-up on June 30, 2010. We 
enrolled two cohorts to allow us to simultaneously assess 
the eﬀ ect of the intervention when patients became 
eligible for ART initiation, and for individuals on long-
term ART. Patients in cohort 1 were adults (aged 
≥16 years) with CD4 counts of 350 cells per μL or less 
who had not yet started ART. They were either eligible for 
ART (CD4 ≤200 cells per μL) or likely to become eligible 
during the trial (CD4 201–350 cells per μL). They were 
followed up for at least 12 months. Patients in cohort 2 
were adults who had already received ART for at least 
6 months and were being treated at the time of 
enrolment. In clinics with more than 100 patients eligible 
for cohort 2, a random sample was taken electronically 
(sample size proportional to total number of eligible 
patients); in other clinics, all eligible patients were 
included. We excluded patients from both cohorts if they 
did not return to their clinic after enrolment, because 
they needed to visit a clinic more than once to initiate 
ART after obtaining CD4 results in cohort 1 or to be 
potentially exposed to the intervention in cohort 2.
The trial protocol was approved by the research ethics 
committees of the faculties of health sciences at the 
University of Cape Town (Cape Town, South Africa) and 
the University of the Free State (Bloemfontein, South 
Africa). Clinic managers provided written informed 
consent to take part in the trial. Informed consent was 
not requested from patients because the intervention 
was educational and man agerial, and was aimed at entire 
clinics and their staﬀ , not at individual patients, so all 
patients in the same clinic would be exposed to the same 
intervention irrespective of whether they consented to 
participate.10,11 Patients in intervention clinics were given 
written information about the trial and the intervention. 
We adhered to ethical principles for use of medical 
records for research without patients’ consent:10,12 the 
research had clear public beneﬁ t; we obtained approval 
for the study from lead doctors and nurses managing the 
programme; use of data for research did not aﬀ ect 
individuals’ care; data were already being used by the 
research team for programme assessment on behalf of 
the provincial health department; and data conﬁ dentiality 
was strictly enforced. Only speciﬁ c data managers had 
access to personal identiﬁ ers. Anonymised data were 
provided only to the principal investigators (LF, MOB), 
the lead statistician, and a health economist. With 
hundreds of patients in each clinic, individuals could not 
be identiﬁ ed from clinic names.
Randomisation and masking
Clinics and their patients were randomly assigned to 
either of two parallel groups. Randomisation was done 
within nine strata—one for each referral hospital in 
the province—to avoid confounding of outcomes by 
variation in care provided by doctors in each hospital. 
One stratum contained four clinics and another two 
clinics; the even numbers meant that randomisation 
could be done in a 1:1 ratio. The other seven strata 
contained odd numbers of clinics and were randomly 
allocated to have either one more or one less intervention 
clinic than control clinics with simple random sampling 
in nQuery Advisor. Six strata each had three clinics. 
Three of those were rand omised with a ratio of two 
intervention clinics to one control clinic. The remaining 
three were randomised with a ratio of one intervention 
clinic to two control clinics. The last stratum had seven 
clinics, and was randomised with a ratio of four 
intervention clinics to three control clinics. Within each 
stratum, clinics were randomly assigned to intervention 
or control according to sequences of random numbers in 
a random number table (even numbers for control and 
odd numbers for intervention), with separate sequences 
for each stratum. In total, we had 16 intervention clinics 
and 15 control clinics. The trial statistician (CL) undertook 
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the randomisation before the trial started. Masking of 
patients and clinicians was not possible because imple-
mentation of the inter vention was obvious. The interim 
analysis was blind, but data analysts were not masked 
after the database was locked for ﬁ nal analysis. 
Procedures
The model of care in the control clinics was the standard 
of HIV and ART care in provincial health services of the 
Free State before the trial, and was continued during the 
trial (appendix). It was consistent with public sector health 
services in most parts of South Africa. Patients diagnosed 
with HIV infection were referred to desig nated nurse-led 
clinics to establish whether they were eligible for ART. 
According to treatment protocols at the time, adults were 
eligible for ART when their CD4 count was less than 
200 cells per μL, they had had stage IV HIV infection 
(AIDS),13 or were pregnant with a CD4 count of less than 
350 cells per μL.14 Patients not yet eligible for ART received 
routine care, such as regular CD4 testing, until they 
became eligible. Patients eligible for ART were referred to 
ART treatment sites in hospital outpatient departments 
for initiation of treatment and review of ART prescriptions 
every 3–6 months, both done by a doctor. To comply with 
national regulations that require ART to be dispensed by 
or under the supervision of pharmacists, who were not 
always located in clinics (appendix), drugs were dispensed 
at treatment sites in patient-named packages, then 
delivered to clinics where nurses issued them to patients 
every month in-between doctor visits. In some remote 
areas, visiting doctors provided ART initiation and on-site 
represcription in nurse-led clinics. Nurses in both control 
and interven tion clinics continued to receive educational 
outreach training in the use of PALSA PLUS, which 
includes management of HIV infection and AIDS but not 
ART prescribing. Control clinics continued to receive 
routine managerial support and monitoring.
Intervention clinics implemented STRETCH (appen-
dix).15 Care of patients with HIV infection diﬀ ered 
from control clinics in several ways. Prescribing nurses 
received at least four educational outreach training 
sessions about ART prescribing and side-eﬀ ects with a 
special edition of the PALSA PLUS guidelines, which 
included algorithms to start and to monitor patients on 
ART, and to identify those needing referral to a doctor.15 
Patients had to meet certain criteria for nurse initiation 
and represcription of ART (appendix). Patients who did 
not meet these criteria were referred to doctors who, 
unlike nurses, were authorised to initiate tailored 
regimens, to change prescriptions, and to prescribe 
second-line drugs.
Nurse middle managers, who had already been trained 
as outreach trainers for PALSA PLUS, participated in an 
additional 2·5 day training course about STRETCH and 
delivered STRETCH educational outreach training to all 
nursing staﬀ  at every intervention clinic. After training, 
103 nurses in intervention clinics were registered with 
the Free State’s Pharmaceutical Services Department and 
authorised to initiate ﬁ rst-line ART drugs and repeat 
ART prescriptions during the trial. 24 doctors who 
supported these nurses were familiarised with the 
guidelines by the STRETCH trial co-ordinator (a doctor 
experienced in care of patients with HIV infection; KU).
The intervention was implemented in three phases to 
give nurses time to gain conﬁ dence with ART. First, 
training was delivered and the STRETCH trial co-
ordinator visited every intervention clinic to establish a 
STRETCH team who were responsible for support of 
phased decentralisation of care. Second, nurses assumed 
responsibility for represcribing ART for patients already 
receiving treatment. The care for all stable patients given 
ART was consolidated in their clinic, so they did not need 
to travel to another treatment site for repre scriptions. 
Third, nurses began to initiate ART in eligible patients. 
The rate of implementation was set by clinic staﬀ , 
allowing well functioning clinics to progress rapidly, 
Figure 1: Trial proﬁ le for cohort 1
ART=antiretroviral therapy. *105 of these patients died after the trial started. †119 of these patients died after the 
trial started.
16 clinics allocated to intervention 15 clinics allocated to control
31 clinics providing ART 
6159 patients assessed for eligibility 4923 patients assessed for eligibility 
769 patients ineligible
61 died before the trial started
28 started ART before the trial started
14 relocated to a non-trial clinic
before the trial started
666 did not seek care after the trial 
started and were assumed to be 
lost to follow-up*
1061 patients ineligible
42 died before the trial started
23 started ART before the trial started
17 relocated to a non-trial clinic 
before the trial started
979 did not seek care after the trial 
started and were assumed to be 
lost to follow-up†
455 patients not linked to death register 
so vital status at end of trial unknown
159 had visited clinic in 
previous 3 months
296 had not visited clinic in 
previous 3 months
447 patients not linked to death register so 
vital status at end of trial unknown
144 had visited clinic in 
previous 3 months
303 had not visited clinic in 
previous 3 months
5390 eligible patients enrolled
5390 patients analysed
3862 eligible patients enrolled
3862 patients analysed
3407 patients with known vital status at 
end of trial
747 died during follow-up
49 died after trial completed
2454 not known to have died
157 visited the health service 
after trial completion
4943 patients with known vital status at 
end of trial
997 died during follow-up
56 died after trial completed
3743 not known to have died
147 visited the health service 
after trial completion
See Online for appendix
Articles
892 www.thelancet.com   Vol 380   September 8, 2012
while others took longer times. Implementation was 
phased between January, and December, 2008.
All 16 intervention clinics successfully implemented 
phases one and two; two clinics could not implement 
phase three because of diﬃ  culties with staﬃ  ng and drug 
distribution, but remained in the trial. In each random-
isation stratum, the ﬁ rst date on which patients in 
intervention and control clinics were enrolled in the trial 
was the date that the last intervention clinic started 
implementation of phase three to ensure that patients in 
both groups were enrolled at similar times. In the two 
strata with the intervention clinics unable to proceed to 
phase three, enrolment of patients in intervention and 
control clinics started on Dec 1, 2008.
Data for individual patients were obtained from routine 
electronic medical records that had been implemented as 
part of the treatment programme in 27 clinics. At every 
clinical visit, information was written on paper forms by 
clinicians and entered into the province’s computer 
system by clerks in the clinic. At the four clinics without 
electronic records, research ﬁ eldworkers entered speciﬁ c 
variables from paper forms in patients’ folders into an 
electronic database.
We identiﬁ ed deaths from programme data and by 
linkage with the national mortality register with national 
identity numbers. The national mortality register is 
based on death certiﬁ cation and records 90% of all 
deaths,16 including those that occur at home or in hospital 
that are not noted by the ART programme. We linked 
individuals’ medical record data with the provincial 
health department’s laboratory, hospital admission, and 
tuberculosis databases.
Data were downloaded to a central database every 
week. We implemented routine checks of data quality to 
minimise missing and unreliable data, prioritising 
variables used to assess eligibility and primary outcome 
measures. For example, patients with missing national 
identity numbers, or numbers that did not match their 
recorded date of birth or did not conform to the standard 
identity number algorithm used in South Africa were 
identiﬁ ed every 2–4 weeks. Eight research ﬁ eldworkers 
travelled to the trial clinics and searched for missing 
information in patients’ paper records. A dedicated 
database manager co-ordinated data collection, manage-
ment, and linkage, and reported weekly on enrolment, 
follow-up, and data quality.
The primary outcome for cohort 1 was time from 
enrolment to death. Each patient’s follow-up was 
censored 12–18 months after enrolment, depending on 
whether patients were enrolled towards the end or 
beginning of the process, to ensure comparable follow-
up across clinics that started implementation early or 
late. Secondary outcomes were measures of health status 
(changes in weight and CD4 cell counts, viral loads, 
hospital admissions, and inpatient days) and indicators 
of quality of care (ART initiation, time from enrolment to 
start of ART, detection of tuberculosis, co-trimoxazole 
provision, programme retention 1 year after enrolment, 
baseline CD4 cell count in patients who started ART, and 
clinic consultations with nurses and doctors).
For cohort 2, the primary outcome was the proportion 
with undetectable viral loads (<400 copies per mL) 
1 year after enrolment. Secondary outcomes were 
measures of health status (time to death censored 
12–18 months after enrolment, changes in weight and 
CD4 cell counts, hospital admissions, and inpatient 
days) and indicators of quality of care (programme 
retention, diagnosis of tuberculosis, co-trimoxazole 
pro vision, switching of ART regimens, and clinic 
consultations with nurses and doctors).
Statistical analysis
For cohort 1, sample size was calculated for a superiority 
trial, because we hoped that STRETCH would increase 
access to ART and thus reduce mortality in the inter-
vention group. We analysed previous programme data 
Figure 2: Trial proﬁ le for cohort 2
ART=antiretroviral therapy. *22 of these patients died after the trial started. †22 of these patients died after the 
trial started. ‡After 12 months of follow-up, patients had been recorded as withdrawn or relocated, or they had 
had no clinic visit or laboratory test in the previous 6 months, and we had no documentation of death. 
16 clinics allocated to intervention 15 clinics allocated to control
31 clinics providing ART 
6415 patients assessed for eligibility 6479 patients assessed for eligibility 
3029 eligible patients enrolled
3029 patients analysed
3202 eligible patients enrolled
3202 patients analysed
3000 patients not sampled
386 patients sampled but ineligible
18 died before the trial started
288 relocated to a non-trial clinic 
before the trial started
80 did not seek care after the trial 
started and were assumed to be 
lost to follow-up*
3147 patients not sampled
130 patients sampled but ineligible
26 died before the trial started
28 relocated to a non-trial clinic before 
the trial started
76 did not seek care after the trial 
started and were assumed to be lost 
to follow-up†
546 patients had no viral load available 
for analysis
75 died
11 relocated
30 withdrew from ART programme
105 were lost to care‡
325 in care but viral loads missing
2656 patients had 12-month viral load 
available for analysis
447 patients had no viral load available
for analysis
66 died
11 relocated
6 withdrew from ART programme
123 were lost to care‡
241 in care but viral loads missing
2582 patients had 12-month viral load 
available for analysis
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for patients with initial CD4 counts of 350 cells per μL or 
less in the trial clinics between 2004, and 2007, and noted 
that 29% of patients followed up for at least 1 year died 
within that year, with an intra-clinic correlation coef-
ﬁ cient (ICC) of 0·01. A sample size of 6000 (3000 per 
group) would provide 90% power to detect a 6% 
diﬀ erence in 1-year mortality (24% vs baseline frequency 
of 30%) at the 5% signiﬁ cance level (two-sided), assuming 
ICC was 0·01. On the basis of a 10% dropout rate in our 
previous trial,7 the sample size was increased to 7400. 
This increased sample size was a conservative adjustment 
with the denominator (1–[rate of loss to follow-up])²— 
ie, 6400/(0·9²)—which accounts for the dropout in the 
intervention group and the proportion receiving the 
standard of care.17 We planned for, and completed, an 
interim analysis 1 year after recruitment started. Neither 
of the prespeciﬁ ed stopping rules (diﬀ erence between 
groups in either primary outcome with p<0·001)10 for 
either cohort were met, and the trial monitoring 
committee recommended that the trial continue. How-
ever, the analysis of pooled data showed that the 1-year 
mortality rate was lower than had been previously 
assumed; therefore, more patients were enrolled into 
cohort 1 than was originally planned.
For cohort 2, sample size was calculated for an 
equivalence trial, because we hoped to show that nurse-
led ART would be as eﬀ ective in maintenance of viral 
suppression as is doctor-led treatment. In previous 
programme data, 82% of patients who had received ART 
for 12 months had undetectable viral loads, with an ICC 
of 0·005. A sample size of 4000 (2000 per group) would 
provide 90% power to show equivalence between groups 
with a 6% equiva lence limit, with 5% signiﬁ cance and an 
ICC of 0·005. To allow for 10% dropout, the sample size 
was increased to 4900 (ie, 4000/[0·9²]). This 6% equiv-
alence limit was smaller than was the 9% equivalence 
limit for viral suppression used in the Jinja trial.3 The 
interim analysis of pooled data showed that the 
proportion of patients with a measured viral load 
measured after 1 year was lower than had been previously 
assumed; therefore more patients were enrolled into 
cohort 2 than was originally planned.
Eﬀ ects of the intervention were estimated by com-
parisons of patients in the intervention and control 
groups with multiple regression models and Huber-
White robust adjustment of errors for intra-cluster 
correlation of outcomes; they were stratiﬁ ed by ran-
domisation strata with Stata (version 11.1). All clinics and 
patients were analysed in the treatment group to which 
they were randomly assigned (intention-to-treat). Time 
from enrolment to death was analysed with Cox 
proportional hazards models. Time from enrolment to 
ART initiation was analysed by competing risks 
regression,6 with death as a competing risk. For these 
time-to-event analyses, follow-up was censored on 
June 30, 2010, or 18 months after enrolment, whichever 
was earlier, thus providing 12–18 months of follow-up.
For the preplanned subgroup analysis of patients in 
cohort 1, we included an allocation-subgroup interaction 
term in the Cox model to separately estimate the eﬀ ect of 
the intervention on survival in patients with CD4 counts 
higher and lower than 200 cells per μL at enrolment. We 
used binomial regression to estimate diﬀ erences in 
proportions of patients with suppressed viral loads, and 
other secondary outcomes in cohort 2. We calculated risk 
ratios for secondary binary outcomes for cohort 1. We 
used linear regression to compare changes in CD4 count 
and weight in both cohorts, by comparing values at the 
end of follow-up while adjusting for the corresponding 
baseline values (ANCOVA).18 Poisson regression was 
Intervention group Control group
Cohort 1
Number of patients 5390 3862
Women 3604 (67%) 2681 (69%)
Age (years) 36 (30–43) 35 (29–42)
National identity number recorded 4767 (88%) 3184 (82%)
CD4 (cells per μL) 141 (70–201) 137 (70–197)
0–49 934 (17%) 678 (18%)
50–99 949 (18%) 720 (19%)
100–199 2141 (40%) 1547 (40%)
200–350 1366 (25%) 917 (24%)
WHO stage recorded* 3057 (57%) 1719 (45%)
Stage I 1582/3057 (52%) 551/1719 (32%)
Stage II 637/3057 (21%) 470/1719 (27%)
Stage III 725/3057 (24%) 653/1719 (38%)
Stage IV 113/3057 (4%) 45/1719 (3%)
Weight recorded 4400 (82%) 2875 (74%)
Weight (kg) 59 (14) 58 (14)
Present tuberculosis 301 (6%) 200 (5%)
Admitted in the year before enrolment 392 (7%) 313 (8%)
Cohort 2
Number of patients 3029 3202
Women 2113 (70%) 2332 (73%)
Age (years) 38 (32–44) 38 (32–45)
National identity number recorded 2859 (94%) 2958 (92%)
Duration on ART (months) 13·9 (6·8–21·7) 13·7 (7·3–22·3)
ART regimen
First line (stavudine, lamivudine, efavirenz) 1846 (61%) 2056 (64%)
First line (stavudine, lamivudine, nevirapine) 1012 (33%) 1011 (32%)
Second line (zidovudine, didanosine, lopinavir) 37 (1%) 28 (1%)
Other 109 (4%) 100 (3%)
Not known 25 (1%) 7 (<1%)
Viral load <400 copies per mL 2378 (79%) 2507 (78%)
Weight recorded 2886 (95%) 3128 (98%)
Weight (kg) 61 (13) 62 (13) 
Present tuberculosis 241 (8%) 186 (6%)
Admitted in the year before enrolment 282 (9%) 299 (9%)
Data are n (%), median (IQR), n/N (%), or mean (SD). ART=antiretroviral theraoy. *Staged just before initiation of ART, 
usually after enrolment.
Table 1: Baseline characteristics by cohort
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used to estimate incidence rate ratios for count outcomes 
such as clinic visits, accounting for individuals’ duration 
of follow-up. Secondary analyses further adjusted for 
potentially confounding baseline characteristics such as 
presence of a national identiﬁ cation number (potentially 
aﬀ ecting ascertainment of death), baseline CD4 cell 
count, age, and sex.
This trial is registered, number ISRCTN46836853.
Role of the funding source
The sponsors of the study had no role in the study 
design, data collection, data analysis, data interpretation, 
or writing of the report.  The corresponding author 
had full access to all the data in the study, and LF and 
MOB share ﬁ nal responsibility for the decision to 
submit for publication. 
Results
Figures 1 and 2 show the trial proﬁ les for each cohort. All 
31 clinics completed the trial. Median follow-up was 
16·3 months (IQR 12·2–18·0) in cohort 1 and 
18·0 months (18·0–18·0) in cohort 2. In cohort 1 
(ﬁ gure 1), the median number of patients enrolled per 
clinic was 210 in the intervention group (IQR 154–323) 
and 260 (143–345) in the control group. More patients 
were enrolled in the intervention group than in the 
control group because it had one more clinic and, by 
chance, two intervention clinics had high numbers of 
eligible patients (1377 and 959 compared with a 
maximum of 596 in control clinics). Median duration of 
follow-up in this cohort was 16·4 months (IQR 12·4–18·0) 
in the intervention group and 16·3 months (11·5–18·0) 
in the control group. In cohort 2 (ﬁ gure 2), the median 
number of patients enrolled per clinic was 176 (97–251) 
in the intervention group and 134 (96–349) in the control 
group. Median duration of follow-up in cohort 2 was 18·0 
months (18·0–18·0) in both groups. Control group 
clinics tended to be smaller and were more likely to have 
on-site doctor support: 8/15 (53%) of control clinics and 
5/16 (31%) of intervention clinics had a full or part time 
doctor available for on-site ART initiation. Table 1 shows 
patients’ baseline characteristics.
In cohort 1, 997 (20%) of 4943 patients with known vital 
status at the end of the trial analysed in the intervention 
group and 747 (19%) of 3862 analysed in the control 
group died (ICC 0·008; ﬁ gure 1). Time to death did not 
diﬀ er between groups (table 2, ﬁ gure 3). Adjustment for 
baseline characteristics did not change this result (table 2, 
appendix). The preplanned subgroup analysis10 showed 
that intervention-group patients with CD4 counts of 
201–350 cells per μL at enrolment had a 27% lower risk of 
death than did those in the control group, but this 
diﬀ erence was not sig niﬁ cant; we recorded no diﬀ erence 
between groups in patients with CD4 counts of 200 cells 
per μL or less at enrolment (table 2, ﬁ gure 3). In patients 
with CD4 counts of 201–350 cells per μL, adjustment for 
charac teristics strengthened the association between the 
inter vention and mortality (table 2).
With pooling of patients in intervention and control 
groups in cohort 1, ART was associated with a 47% lower 
risk of death than no treatment (hazard ratio [HR] 0·53, 
95% CI 0·42–0·68). The strength of this association did 
not diﬀ er between intervention and control groups 
(data not shown). Detection of tuberculosis, programme 
retention, and CD4 cell count at the end of follow-up 
were higher in the intervention group than in the control 
group (table 3). In the intervention group, 965 (26%) of 
3712 ART initiations were by a nurse; in the control 
group, none were.
In cohort 2, viral suppression a year after enrolment 
did not diﬀ er between intervention and control patients, 
and the prespeciﬁ ed equivalence limit of 6% was met 
(table 4). Adjustment for patients’ baseline characteristics 
did not change this result (appendix). Gains in CD4 cell 
count and weight (data not shown), and probability of 
switching ART drugs (table 4), were higher in the 
intervention group than in the control group. 47 (77%) of 
61 patients in the intervention group who switched 
regimens had documentation of detectable viraemia 
beforehand, compared with 20 (74%) of 27 patients in the 
Intervention group Control group Hazard ratio 
(95% CI)
p value Adjusted hazard 
ratio (95% CI)†
Adjusted
p value
Number 
of deaths
Person-years 
at risk
Hazard of death per 
100 person-years at 
risk (95% CI)*
Number 
of deaths
Person-years 
at risk
Hazard of death per 
100 person-years at 
risk (95% CI)*
Primary analysis (n=9252) 997 74 256 1·34 (1·26–1·43) 747 51 861 1·44 (1·34–1·55) 0·94 (0·76–1·15) 0·532 0·92 (0·76–1·12) 0·401
Subgroup analysis: baseline 
CD4 count 201–350 cells 
per μL (n=2283)
102 20 710 0·06 (0·03–0·10) 90 13 224 0·68 (0·55–0·84) 0·73 (0·54–1·00)‡ 0·052 0·70 (0·52–0·95)§¶ 0·020
Subgroup analysis: baseline 
CD4 count ≤200 cells per μL 
(n=6969)
895 53 546 1·67 (1·56–1·78) 657 38 637 1·70 (1·57–1·83) 1·00 (0·80–1·24) 0·999 0·94 (0·77–1·16) 0·577
*Binomial exact conﬁ dence intervals. †Adjusted for patients’ age, sex, CD4 cell count at enrolment, and record of an identity number. ‡Interaction between group and CD4 cell count stratum p=0·050. §Adjusted 
for patients’ age, sex, and record of an identity number. ¶Interaction term between group and CD4 cell count stratum p=0·049. 
Table 2: Eﬀ ect of the intervention on time from enrolment to death in cohort 1
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control group, suggesting that the increased numbers of 
switches in the intervention group were appropriate. 
Time to death did not diﬀ er between groups (ﬁ gure 3).
Patients in the intervention group visited nurses 
more often than did those in the control group in both 
cohorts, and doctors in cohort 1 (appendix). Adverse 
events of interest were deaths and admissions to hospital 
(ﬁ gures 1, 2, appendix).
Discussion
We have shown that task shifting of the primary 
responsibility for ART from doctors to primary-care 
nurses in a large-scale public sector programme did not 
improve survival of patients not yet taking ART with CD4 
counts of 350 cells per μL or less, but did in patients with 
CD4 counts of 201–350 cells per μL, although the 
diﬀ erence was not signiﬁ cant. It did achieve its second 
primary goal of equivalent viral load suppression in 
patients already taking ART at enrolment. The 95% CI 
for the comparison of viral load suppression were more 
precise in our study than in the Jinja trial of ART task 
shifting,3 because our sample size was larger. Addition-
ally, the STRETCH intervention improved several other 
health outcomes and quality indicators. No outcomes 
were worse in intervention groups than in control ones.
Our encouraging evidence supports task shifting of 
ART from doctors to nurses and other health workers, 
which seems essential for ART expansion in South Africa 
and elsewhere in Africa. Since our trial ended in 2010, 
South African national policy has changed to promote 
nurse initiation and management of ART.19 However, if 
such a strategy is implemented without suﬃ  cient clinical 
and management support, it could be less eﬀ ective than 
the STRETCH programme was in our trial.
Our trial was done to a high standard, with enrolment 
exceeding our planned sample sizes, and with data for 
primary outcomes available for 94% of participants. With 
two cohorts of patients, we could simultaneously assess 
eﬀ ects on both short-term and long-term care. Linkage of 
electronic clinical, laboratory, hospital, and mortality data 
made the examination of a wide range of health outcomes 
and indicators of care quality possible for large and 
generalisable samples of patients. However, our study 
was limited by the restriction of follow-up to 18 months. 
Furthermore, we were missing data for weight and CD4 
cell count in both cohorts, and for viral load after 
12 months of ART in cohort 1.
Outside of the trial, the Free State Health Department 
attempted to improve access to doctors so as to accelerate 
ART provision from July, 2008. Doctors who were part 
of the ART programme were instructed to visit speciﬁ c 
clinics to review problem cases, to complete repre-
scriptions, and to initiate pa tients on ART. This change 
in programme might have unintentionally favoured the 
control group if these doctors thereby provided more 
intensive and expert care than would otherwise have 
been available. Intervention clinics were less likely to 
Figure 3: Kaplan-Meier curves of time to death
(A) Cohort 1. (B) CD4 subgroups of cohort 1. (C) Cohort 2.
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have doctor-provided ART initiation on site at the start 
of the trial and by the middle of the study, this disparity 
had increased with on-site doctors at 11 (73%) of 
15 control clinics and seven (44%) of 16 intervention 
clinics. Therefore, a clinic’s ability to expedite ART 
initiation in patients whom nurses thought needed to 
Intervention 
group
Control group Eﬀ ect estimate* p value Intra-cluster 
correlation 
coeﬃ  cient
Regression 
model*
Type Estimate (95% CI)
Started on ART 3712/5390 (69%) 2418/3862 (63%) Risk ratio 1·24 (0·88 to 1·73) 0·218 0·065 Binomial
Time to ART†‡ ·· ·· Subdistribution 
hazard ratio
1·14 (0·92 to 1·43) 0·232 0·065 Competing 
risk
New tuberculosis diagnosis 1057/5390 (20%) 510/3862 (13%) Risk ratio 1·46 (1·18 to 1·81) 0·001 0·051 Binomial
Received co-trimoxazole 
prophylaxis
3899/5390 (72%) 2767/3862 (72%) Risk ratio 1·03 (0·93 to 1·13) 0·608 0·149 Binomial
Programme retention§ 3373/5390 (63%) 2254/3862 (58%) Risk ratio 1·10 (1·04 to 1·16) <0·001 0·019 Binomial
Baseline CD4 cell count of 
patients starting ART
132 (82); n=3470 131 (82); n=2083 Diﬀ erence in 
means
0·102 (–13·1 to 13·4) 0·988 0·030 Linear
Suppressed viral load in patients 
who started ART¶
1706/2375 (72%) 1062/1449 (73%) Risk ratio 0·97 (0·90 to 1·03) 0·324 0·040 Binomial
Proportion with a missing viral 
load in patients who started ART
1274/3712 (34%) 945/2219 (43%) Risk ratio 0·86 (0·71 to 1·04) 0·120 0·014 Binomial
Weight at follow-up (kg) 62·6 (14·0); 
n=2712
62·4 (13·7); 
n=1503
Diﬀ erence in 
means
0·10 (–1·35 to 1·56) 0·884 0·019 Linear
CD4 count at follow-up 
(cells per μL)
161·3 (175·2); 
n=2345
141·7 (161·6); 
n=1544
Diﬀ erence in 
means
22·3 (3·6 to 40·9) 0·021 0·026 Linear
Data are n/N (%) or mean (SD), unless otherwise stated. ART=antiretroviral therapy. *Regression models adjusted for randomisation strata and intra-cluster correlation of 
outcomes. †Follow-up censored, so no mean time to ART listed. ‡Adjusted for the competing risk of death. §Patients were judged to be retained by the programme when 
after 12 months they were alive, were not known to have withdrawn or relocated, and had documentation of a clinic visit or laboratory test in the previous 6 months (if 
started ART or last known CD4 count was less than 200 cells per μL) or in the past 9 months (if they had not started ART and last known CD4 count was more than 200 cells 
per μL). ¶Patients with at least 6 months of ART and viral load results available. 
Table 3: Secondary outcomes in cohort 1
Intervention group Control group Eﬀ ect estimate* p value Intra-cluster 
correlation 
coeﬃ  cient
Regression 
model*
Type Estimate (95% CI)
Primary outcome
Suppressed viral load† 2156/3029 (71%) 2230/3202 (70%) Risk diﬀ erence 1·1% (–2·3 to 4·6) 0·534 0·010 Binomial
Secondary outcomes
Time to death‡ ·· ·· Hazard ratio 1·05 (0·84 to 1·31) 0·684 0·005 Cox
Programme retention§ 2733/3029 (90%) 2926/3202 (91%) Risk diﬀ erence –0·3% (–2·1 to 1·54) 0·758 0·013 Binomial
New tuberculosis 
diagnosis
119/3029 (4%) 113/3202 (4%) Risk diﬀ erence 0·21% (–0·40 to 0·84) 0·487 0·019 Binomial
Received co-trimoxazole 
prophylaxis
2143/3029 (71%) 2578/3202 (81%) Risk diﬀ erence 9·8% (–33·7 to 14·2) 0·424 0·477 Binomial
Change in ART drugs 
during trial
161/3029 (5%) 57/3202 (2%) Risk diﬀ erence 1·25% (0·65 to 1·86) <0·001 0·044 Binomial
Weight at follow-up (kg) 63·0 (13·5); n=2136 63·2 (14·1); n=2271 Diﬀ erence in 
means
0·62 (0·01 to 1·23) 0·045 0·010 Linear
CD4 count at follow-up 
(cells per μL)
438·8 (219·5); n=1733 418·4 (201·8); n=1691 Diﬀ erence in 
means
24·2 (7·2 to 41·3) 0·007 0·007 Linear
Data are n/N (%) or mean (SD), unless otherwise stated. *Regression models adjusted for randomisation strata and intra-cluster correlation of outcomes. †All patients 
enrolled in the trial were included in the denominator; of these 2308/3029 (76%) of patients in intervention group and 2499/3202 (78%) in control group had been 
receiving ART for more than 2 years when viral load was measured; 1084/3029 (36%) patients in intervention group and 1125/3202 (35%) in control group had been 
receiving ART for more than 3 years. ‡Follow-up censored, so no mean time to time to death listed.§Patients were judged to be retained by the programme when after 
12 months they were alive, not known to have withdrawn or relocated, and had documentation of a clinic visit or laboratory test in the previous 6 months. 
Table 4: Primary and secondary outcomes in cohort 2
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be assessed by a doctor might have been reduced in 
intervention groups.
This pragmatic trial realistically shows practical prob-
lems with large-scale implementation of ART in Africa. 
Several reasons could explain why the inter vention did 
not accelerate ART initiation or reduce mortality in 
cohort 1, and why only a quarter of patients who started 
ART had treatment initiated by nurses. First, our 
qualitative research showed that many STRETCH nurses 
were initially hesitant to initiate ART when they had the 
option of referrals to doctors. Second, allocation of 
increased numbers of doctors to control clinics during 
the trial probably placed intervention clinics at a com-
parative disadvantage. Third, diﬃ  culties with funding 
and delivery of ART to clinics reduced STRETCH nurses’ 
ability to initiate ART promptly. For example, initiation of 
ART was suspended for 3 months from November, 2008, 
to February, 2009, because the provincial health depart-
ment temporarily exhausted its ART budget,20 as in other 
countries when donor funding has decreased.21 Fourth, 
during the trial several clinics that were not in the study 
started to provide ART. This change could have reduced 
the workload of trial clinics, thus decreasing the extent to 
which STRETCH could accelerate ART initiation com-
pared with control clinics. The favourable results for 
cohort 1 patients with CD4 counts of 201–350 cells per μL 
at enrolment, and for cohort 2 patients, suggest that 
nurses in intervention clinics could competently build on 
what they had done before—ie, preparation of patients 
for ART initiation and monitoring of those already on 
ART. However, the subgroup analysis of mortality in 
cohort 1 should be interpreted with caution, because the 
diﬀ erence in eﬀ ects between subgroups was moderate, 
the inter vention–subgroup interaction was marginally 
sig niﬁ  cant, and the subgroups deﬁ ned by CD4 cell count 
were not precisely deﬁ ned in advance.
Nurses in the intervention group had little trouble 
with task shifting of represcriptions from doctors, which 
relieved doctors of a heavy burden and enabled them 
to focus on referred patients who were seriously ill. 
Biological evidence that intervention patients received 
more eﬀ ective treatment than did those in the control 
group included the large increase in CD4 cell count in 
both cohorts and weight gain in cohort 1. In cohort 1, 
patients in the intervention group were more likely to 
remain in the programme and to have tuberculosis 
identiﬁ ed than were those in control clinics, and in 
cohort 2, switching of regimens occurred more in inter-
vention than control clinics, indicating that STRETCH 
training and guidelines improved the delivery of appro-
priate care. Increased regimen switching could have 
resulted from nurses having good awareness of adverse 
treatment eﬀ ects or drug resistance, leading to referrals 
to doctors authorised to switch regimens.
Our trial is unique because we included and followed 
up patients who had not yet started ART, and because the 
intervention included nurse initiation of ART. In the two 
most similar trials of ART task shifting—the CIPRA trial 
in South Africa4 and the Jinja trial in Uganda3 (panel)—
treatment was initiated by doctors but followed up by 
nurses and non-medical ﬁ eld oﬃ  cers, respectively. These 
trials3,4 also provided substantially more training than we 
did in our trial, and patients who had not yet started ART 
were not followed up. However, our ﬁ nding that 
outcomes were no worse in intervention than in control 
groups is in keeping with their results.
The high mortality of cohort 1 patients is of concern, 
although it is lower than the proportion who died within 
1 year of enrolment in these clinics before 2008 (29%), and 
much lower than the proportion who died in the province 
before 2006 (87%),5 continuing the trends of decreasing 
mortality in South African ART programmes over time.24
STRETCH is thus an eﬀ ective and feasible method of 
rapidly expanding ART provision in South Africa and 
other countries where shortages of doctors restrict 
access to ART. The increased rates of clinic visits to both 
doctors and nurses in cohort 1 could constrain imple-
mentation, although the lower rates and duration of 
Panel: Research in context
Systematic review
We searched PubMed and Google Scholar for randomised trials assessing task shifting of 
antiretroviral therapy (ART) published at any time before Oct 31, 2011, with the search 
terms “antiretroviral”, “task-shifting” or “nurse” or “community health worker”, and 
“trial”. We identiﬁ ed three randomised trials of ART task shifting: cluster-randomised trials 
from Uganda3 and Kenya,22 and the individually randomised CIPRA trial from South 
Africa.4 Another trial from Uganda23 was excluded because it investigated the addition of 
community-based follow-up to clinic-based care, and so did not entail task shifting as 
deﬁ ned by WHO.1 The Ugandan3 and Kenyan22 trials compared clinic-based with 
community-based ART follow-up. The CIPRA trial4 compared ART follow-up by nurses 
with follow-up by doctors, both provided at clinics. After ART initiation in one clinic, the 
Ugandan study3 was based in 44 geographical areas, but the Kenyan one22 was in only one 
clinic and CIPRA4 was in two. All three trials had similar outcomes (viral load suppression, 
CD4 cell counts, and loss to follow-up) for patients on ART. In the Ugandan3 and South 
African4 trials, ART was initiated by doctors. None of these trials enrolled patients who 
had not yet started ART but were eligible or would soon be eligible. All three trials showed 
no signiﬁ cant diﬀ erence in outcomes.
Interpretation
Our results are in keeping with the Ugandan,3 Kenyan,22 and CIPRA4 trials and support 
provision of ART follow-up care by non-physicians. The generalisability and feasibility of 
implementation of our programme are supported by its basis in many clinics throughout 
a province. The suppression of viral load in patients who were already receiving ART at 
enrolment is similar to that reported for the Ugandan trial.3 However, our trial provides 
original evidence of the eﬀ ectiveness of a nurse-led system on the clinically challenging 
task of ART initiation, including for patients recently or newly enrolled in the treatment 
programme. We have shown that expansion of nurses’ roles to include ART initiation can 
be done safely and can improve health outcomes and quality of care, but that time to ART 
initiation or mortality did not change. Several observational studies support the role of 
non-physician clinicians in provision of ART care, but few are of programmes in which 
ART initiation is led by non-physician clinicians.2 Taken together, our study and the others 
we have identiﬁ ed suggest that the present approach of non-physician clinicians 
expanding ART programmes in resource-constrained environments is safe and feasible.
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admission in the intervention group than in the control 
group in cohort 1, and the task shifting of clinic visits 
from doctors to nurses in cohort 2, indicate that 
resources are used more eﬃ  ciently with the programme 
than without. The cost-eﬀ ectiveness of the interven-
tion will be reported separately. The suitability of this 
approach in countries where access to physicians is even 
more restricted than in South Africa or is non-existent 
should be assessed in a separate trial. Our results are 
relevant to other countries in Africa because they show 
that non-physician health workers can provide compre-
hensive ART care, including ART initiation, after just 
four additional short training sessions. Our training 
methods and guideline design have been previously 
assessed and are already being implemented in The 
Gambia and Malawi.25,26
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